Asthma: pathogenesis and novel drugs for treatment

@article{Olin2014AsthmaPA,
  title={Asthma: pathogenesis and novel drugs for treatment},
  author={Jason T. Olin and Michael E. Wechsler},
  journal={BMJ : British Medical Journal},
  year={2014},
  volume={349}
}
  • J. OlinM. Wechsler
  • Published 24 November 2014
  • Medicine, Biology
  • BMJ : British Medical Journal
Asthma affects almost 20 million people in the United States and more than 300 million people worldwide. Of these, 10-15% have severe asthma, which is refractory to commonly available drugs. New drugs are needed because those that are currently available cannot control symptoms and exacerbations in all patients and can cause adverse reactions. In the past 10 years, there have been substantial advances in the understanding of asthma genetics, airway biology, and immune cell signaling. These… 

BRONCHIAL ASTHMA: A GLOBAL HEALTH PROBLEM

The mainstay of future research is on the clinical efficacy of newer agents, the effect of biological agents on severe asthma patients, and the understanding at cellular level of corticosteroid resistant asthma is needed to reduce the morbidity of asthma worldwide.

Novel glucocorticoid receptor agonists in the treatment of asthma

The generation of gene expression ‘fingerprints’ produced by different GR agonists in target and off-target human tissues could be useful in identifying drug candidates with an improved therapeutic ratio.

Current and Emerging Biologic Therapies for Asthma and COPD

New research into the underlying pathophysiology of asthma and COPD has led to novel targeted therapies that address the underlying pathways that cause these obstructive disorders, and the new biologics are generally safe and well tolerated.

Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review

Well-designed randomized controlled trials are needed in asthmatic patients to confirm the potentially positive benefit/risk ratio of each specific SEGRA and to optimize the development strategy of these agents in respiratory medicine.

Selecting the right biologic for your patients with severe asthma.

  • L. MankaM. Wechsler
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2018

Modern Technologies of Bronchial Asthma Control in Children (Review)

There is a search for crucially new approaches to asthma treatment with due consideration of the disease phenotypes and endotypes including development and practical application of pharmaceutical drugs with anti-cytokine and anti-mediator effects.

New biologics for allergic diseases

ABSTRACT Introduction: Allergic conditions such as asthma and atopic dermatitis have a high prevalence but represent a heterogeneous group of diseases despite similar clinical presentation and

Asthma and COVID-19: Emphasis on Adequate Asthma Control

Clinicians are advised to try to achieve adequate disease control in asthmatics as it may reduce incidences and severity of exacerbations especially from SARS-CoV-2 infection.

Anti-inflammatory dosing of theophylline in the treatment of status asthmaticus in children

Low-dose theophylline may have a positive effect in acute status asthmaticus and further research with a prospective, randomized, double-blinded, placebo controlled trial may be warranted to confirm and extend the findings.

Modern Technologies of bronchial Asthma Control in Children (Review)

It is still a problem to obtain the disease control in most patients indicating the necessity for searching new therapeutic approaches, and there is a search for crucially new approaches to asthma treatment with due consideration of the disease phenotypes and endotypes.
...

References

SHOWING 1-10 OF 193 REFERENCES

New drugs for asthma

  • P. Barnes
  • Medicine, Biology
    Nature Reviews Drug Discovery
  • 2004
There is a search for new therapies, particularly safe and effective oral treatments and those that are more efficacious in severe asthma, and new therapies in development include mediator antagonists and inhibitors of cytokines, although these therapies might be too specific to be very effective.

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

Current studies of compounds targeting the interleukin-4/interleuk in-13 pathway are summarised to provide a rationale for the development of such compounds for this use and provide a new therapeutic modality for patients with uncontrolled severe asthma.

Th17-Associated Cytokines as a Therapeutic Target for Steroid-Insensitive Asthma

This review focuses on the pathogenetic role of Th17 cells and their associated cytokines in steroid-insensitive asthma and discusses the prospects of novel therapeutic options targeting the Th17 signaling pathway.

Lebrikizumab treatment in adults with asthma.

Lebrikizumab treatment was associated with improved lung function and patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikIZumab than did patients with low periOSTin levels.

The potential use of tyrosine kinase inhibitors in severe asthma

Targeting key inflammatory and remodeling pathways engaged across subphenotypes with tyrosine kinase inhibitors appears to hold promise in treatment of severe asthma.

The metabolomics of asthma: novel diagnostic potential.

This article outlines the more recent work that has been done to develop the metabolomic profile of asthma and describes how this profile might vary with disease severity.

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.

These promising data suggest that IL-4R is safe and effective in the treatment of moderate persistent asthma.

Omalizumab for asthma in adults and children.

An updated review of NICE guidance recommends omalizumab for use as add-on therapy in adults and children over six years of age with inadequately controlled severe persistent allergic IgE-mediated asthma who require continuous or frequent treatment with oral corticosteroids and a main focus of the updated review is subcutaneous administration, as this route is currently used in clinical practice.
...